Rossari Biotech Management

Management criteria checks 4/4

Rossari Biotech's CEO is Sunil Chari, appointed in Jan 2003, has a tenure of 21.25 years. total yearly compensation is ₹11.13M, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 30.93% of the company’s shares, worth ₹13.02B. The average tenure of the management team and the board of directors is 2.6 years and 4.4 years respectively.

Key information

Sunil Chari

Chief executive officer

₹11.1m

Total compensation

CEO salary percentage	100.0%
CEO tenure	21.3yrs
CEO ownership	30.9%
Management average tenure	2.6yrs
Board average tenure	4.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Sunil Chari's remuneration changed compared to Rossari Biotech's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	₹1b
Sep 30 2023	n/a	n/a	₹1b
Jun 30 2023	n/a	n/a	₹1b
Mar 31 2023	₹11m	₹11m	₹1b
Dec 31 2022	n/a	n/a	₹1b
Sep 30 2022	n/a	n/a	₹995m
Jun 30 2022	n/a	n/a	₹1b
Mar 31 2022	₹10m	₹10m	₹977m
Dec 31 2021	n/a	n/a	₹957m
Sep 30 2021	n/a	n/a	₹948m
Jun 30 2021	n/a	n/a	₹892m
Mar 31 2021	₹9m	₹9m	₹802m
Dec 31 2020	n/a	n/a	₹729m
Sep 30 2020	n/a	n/a	₹695m
Jun 30 2020	n/a	n/a	₹666m
Mar 31 2020	₹8m	₹7m	₹653m
Mar 31 2019	₹5m	n/a	₹457m
Mar 31 2018	₹9m	n/a	₹254m

Compensation vs Market: Sunil's total compensation ($USD133.59K) is below average for companies of similar size in the Indian market ($USD278.32K).

Compensation vs Earnings: Sunil's compensation has been consistent with company performance over the past year.

CEO

Sunil Chari (58 yo)

21.3yrs

Tenure

₹11,130,000

Compensation

Mr. Sunil Srinivasan Chari serves as a Managing Director of Rossari Biotech Limited since September 26, 2019 and serves as its Director since 2009. He is a co-founder of Rossari Biotech Limited in 2003. He...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Edward Menezes	Co-Founder & Executive Chairman	15.3yrs	₹11.12m	30.99% ₹ 13.0b
Sunil Chari	Co-Founder	21.3yrs	₹11.13m	30.93% ₹ 13.0b
Ketan Sablok	Chief Financial Officer	less than a year	no data	no data
Mikhail Menezes	Director of Technical	no data	no data	0.24% ₹ 101.4m
Shifa Suresh	Vice President of Human Resources & Administration	2.6yrs	no data	no data
Parul Gupta	Company Secretary & Compliance Officer	4.4yrs	₹1.00m	no data
Yash Chari	Director of Marketing & Business Development	no data	no data	0.30% ₹ 125.7m
Sunil V	Chief Human Resource Officer	no data	no data	no data
Puneet Arora	Chief Executive Officer of Textile Chemicals Global	no data	no data	no data
Manasi Nisal	Senior Vice President of Strategy & Business Analytics	less than a year	₹4.00m	no data
Prasad Gadkari	President of Manufacturing	no data	no data	no data

2.6yrs

Average Tenure

48.5yo

Average Age

Experienced Management: 543213's management team is considered experienced (2.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Edward Menezes	Co-Founder & Executive Chairman	15.3yrs	₹11.12m	30.99% ₹ 13.0b
Sunil Chari	Co-Founder	15.3yrs	₹11.13m	30.93% ₹ 13.0b
Aseem Dhru	Independent Director	4.4yrs	₹2.13m	0.00018% ₹ 75.7k
Annoottam Ghosh	Member of Advisory Board	no data	no data	no data
Vikram Gupta	Member of Advisory Board	no data	no data	no data
Goutam Bhattacharya	Independent Director	5.3yrs	₹2.58m	no data
Sharabh Pachory	Independent Director	4.4yrs	₹1.73m	no data
Jean Marcopoulos	Member of Advisory Board	no data	no data	no data
Klaus Karl	Member of Advisory Board	no data	no data	no data
Aparna Sharma	Non-Executive Independent Director	less than a year	no data	no data
Esha Achan	Additional Non-Executive Independent Director	less than a year	no data	no data

4.4yrs

Average Tenure

60.5yo

Average Age

Experienced Board: 543213's board of directors are considered experienced (4.4 years average tenure).

Rossari Biotech Management

Management criteria checks 4/4

Key information

Recent management updates

Rossari Biotech Limited Announces Resignation of Melier Castelino as an Independent Director

Rossari Biotech Limited Appoints Ms. Aparna Sharma , as A Non-Executive, Independent Director, Effective 29Th April, 2023

Rossari Biotech Limited, Annual General Meeting, May 31, 2023

Rossari Biotech Limited, Annual General Meeting, May 31, 2023

Rossari Biotech Limited Announces Resignation of Robin Banerjee as Non-Executive Independent Director

Insufficient new directors

Recent updates

Rossari Biotech Limited to Report Q4, 2024 Results on Apr 29, 2024

Now 20% undervalued

Price target increased by 9.0% to ₹852

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 17%

Price target decreased by 8.4% to ₹782

Second quarter 2024 earnings released: EPS: ₹5.97 (vs ₹4.34 in 2Q 2023)

Rossari Biotech Limited to Report Q2, 2024 Results on Oct 21, 2023

First quarter 2024 earnings released: EPS: ₹5.30 (vs ₹5.21 in 1Q 2023)

Rossari Biotech Limited to Report Q1, 2024 Results on Jul 29, 2023

Rossari Biotech Limited Announces Resignation of Melier Castelino as an Independent Director

Investor sentiment improves as stock rises 16%

Rossari Biotech Limited Appoints Ms. Aparna Sharma , as A Non-Executive, Independent Director, Effective 29Th April, 2023

Upcoming dividend of ₹0.50 per share at 0.1% yield

Rossari Biotech Limited, Annual General Meeting, May 31, 2023

Rossari Biotech Limited, Annual General Meeting, May 31, 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment improves as stock rises 23%

Price target decreased by 9.2% to ₹986

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Rossari Biotech Limited Announces Resignation of Robin Banerjee as Non-Executive Independent Director

Insufficient new directors

Consensus forecasts updated

Consensus forecasts updated

Second quarter 2023 earnings released: EPS: ₹4.34 (vs ₹4.77 in 2Q 2022)

Rossari Biotech Limited to Report Q2, 2023 Results on Nov 05, 2022

First quarter 2023 earnings released: EPS: ₹5.21 (vs ₹4.52 in 1Q 2022)

Rossari Biotech Limited to Report Q1, 2023 Results on Aug 06, 2022

Rossari Biotech Limited Approves Dividend for the Financial Year Ended March 31, 2022, Payable on or After July 21, 2022

Upcoming dividend of ₹0.50 per share

Full year 2022 earnings: EPS misses analyst expectations

Rossari Biotech Limited Recommended Final Dividend for the Financial Year Ended March 31, 2022, Payable on or After July 21, 2022

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Rossari Biotech Limited Proposes Final Dividend for the Financial Year Ended March 31, 2022

Rossari Biotech Limited, Annual General Meeting, Jul 15, 2022

Price target decreased to ₹1,252

Consensus revenue estimates increase by 26%

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Price target decreased to ₹1,330

Second quarter 2022 earnings released: EPS ₹4.77 (vs ₹4.07 in 2Q 2021)

Insider recently sold ₹2.1m worth of stock

Price target increased to ₹1,270

First quarter 2022 earnings released: EPS ₹4.52 (vs ₹3.19 in 1Q 2021)

Rossari Biotech Reportedly in Advanced Talks to Acquire Specialty Chemicals Business

Rossari Biotech Limited (BSE:543213) entered in an agreement to acquire Unitop Chemicals Pvt. Ltd. for approximately INR 4.2 billion.

Full year 2021 earnings released: EPS ₹15.56 (vs ₹13.42 in FY 2020)

Rossari Biotech Limited announced that it expects to receive INR 2.999997816 billion in funding from Malabar Investments, LLC, State Bank of India, Asset Management Arm and other investors

New 90-day high: ₹1,036

Third quarter 2021 earnings released: EPS ₹4.16

Rossari Biotech Limited to Report Q3, 2021 Results on Jan 23, 2021

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day high: ₹859

New 90-day high: ₹839

First half earnings released

Rossari Biotech Limited to Report Q2, 2021 Results on Oct 24, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age